Literature DB >> 17975120

Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004.

Todd S Perlstein1, Reena L Pande, Joshua A Beckman, Mark A Creager.   

Abstract

BACKGROUND: Bilirubin, with recently recognized antioxidant and antiinflammatory activity, has emerged as a candidate for atheroprotection. We hypothesized that higher levels of bilirubin would reduce susceptibility to peripheral arterial disease (PAD). METHODS AND
RESULTS: We analyzed 7075 adults with data available on the ankle brachial index, serum total bilirubin level, and PAD risk factors in the National Health and Nutrition Examination Survey (1999 to 2004), a nationally representative cross-sectional examination of the United States population. A 0.1 mg/dL increase in bilirubin level was associated with a 6% reduction in the odds of PAD (OR 0.94 [95% CI 0.90 to 0.98]) after adjustment for age, gender, race/ethnicity, smoking status, diabetes, hypertension, hypercholesterolemia, chronic kidney disease, CRP, and homocysteine. This result was not dependent on bilirubin levels above the reference range, liver disease, or alcohol intake. The inverse association of bilirubin with PAD tended to be stronger among men (OR 0.90 [95% CI 0.85 to 0.96]) compared with women (OR 0.97 [95% CI 0.91 to 1.04]; P(interaction)=0.05), and was stronger among active smokers (OR 0.81 [95% CI 0.73 to 0.90]) compared with nonsmokers (OR 0.97 [95% CI 0.93 to 1.02]; P(interaction)<0.01).
CONCLUSIONS: Increased serum total bilirubin level is associated with reduced PAD prevalence. This result is consistent with the hypothesis that bilirubin is protective from PAD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975120     DOI: 10.1161/ATVBAHA.107.153262

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  61 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

2.  Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIV-infected adults on stable antiretroviral therapy.

Authors:  Co Hileman; Ct Longenecker; Tl Carman; Gl Milne; D E Labbato; Nj Storer; Ca White; Ga McComsey
Journal:  HIV Med       Date:  2012-05-25       Impact factor: 3.180

3.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

4.  Inverse association between serum total bilirubin levels and diabetic peripheral neuropathy in patients with type 2 diabetes.

Authors:  Eun Sook Kim; Sung Won Lee; Eun Young Mo; Sung Dae Moon; Je Ho Han
Journal:  Endocrine       Date:  2015-04-07       Impact factor: 3.633

5.  Socioeconomic inequality and peripheral artery disease prevalence in US adults.

Authors:  Reena L Pande; Mark A Creager
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-07

6.  Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Authors:  Jessica Milian; Allison B Goldfine; Jonah P Zuflacht; Caitlin Parmer; Joshua A Beckman
Journal:  Acta Diabetol       Date:  2015-01-08       Impact factor: 4.280

7.  Essential roles of Raf/extracellular signal-regulated kinase/mitogen-activated protein kinase pathway, YY1, and Ca2+ influx in growth arrest of human vascular smooth muscle cells by bilirubin.

Authors:  Marlon Stoeckius; Anna Erat; Tatsuya Fujikawa; Makoto Hiromura; Anna Koulova; Leo Otterbein; Cesario Bianchi; Edda Tobiasch; Yossi Dagon; Frank W Sellke; Anny Usheva
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

8.  The Relationship among Homocysteine, Bilirubin, and Diabetic Retinopathy.

Authors:  Ho Chan Cho
Journal:  Diabetes Metab J       Date:  2011-12-26       Impact factor: 5.376

9.  Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech
Journal:  Diabetologia       Date:  2013-01-17       Impact factor: 10.122

10.  Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men.

Authors:  Michel M Joosten; Jennifer K Pai; Monica L Bertoia; Eric B Rimm; Donna Spiegelman; Murray A Mittleman; Kenneth J Mukamal
Journal:  JAMA       Date:  2012-10-24       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.